More recently, the role of TRAIL as a mediator of amyloid-beta neurotoxicity has been explored as a potential therapeutic target for the treatment of AD in a triple transgenic mouse model of AD [82]. This evidence concerns the gene TNFSF10 and Alzheimer disease.